Categories AlphaGraphs, Earnings, Finance

BlackRock misses street estimates in Q2

Investment management firm BlackRock Inc (NYSE: BLK) reported second-quarter revenues that fell 2% year-over-year to $3.52 billion, hurt by lower securities lending revenue and performance fees. Analysts were, on an average, expecting $3.57 billion.

Performance fees decreased $27 million from the second quarter of 2018, primarily reflecting lower revenue from long-only equity products.

blackrock misses revenue and earnings estimate inQ2 2019

Meanwhile, technology services revenue grew 20%, partly helped by the eFront acquisition.

On an adjusted basis, net income fell 4% to $6.41 per share, which also missed the street consensus of $6.50 per share. The decline in bottom-line reflected lower operating incomes and higher taxes during the quarter.

The New York-based firm generated $151 billion of total net inflows in the second quarter, a record 9% annualized organic asset growth, driven by record fixed income and cash activity.

READ: Strong loan growth drives NII for US Bancorp in Q2

CEO Laurence Fink said, “While organic base fee growth of 3% and the year-over-year revenue decline reflected certain market headwinds, our second-quarter results validate BlackRock’s unique ability to bring together the entire firm to meet clients’ needs in any market environment.”

BLK shares ended its last trading session up 0.89% on Thursday. The stock has gained 22% so far this year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top